Curevac announces dosing of first participant in phase 2 study of modified covid-19 mrna vaccine candidates developed in collaboration with gsk

Phase 2 study initiated at clinical sites in australia with monovalent and bivalent mrna covid-19 vaccine candidates vaccine candidates developed in collaboration with gsk within covid-19 vaccine development program tÜbingen, germany and boston, ma / accesswire / august 1, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the first participant was dosed in the phase 2 study of monovalent and bivalent modified mrna covid-19 vaccine candidates, developed in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking